VERAXA Advances Lead BiTAC Into IND-Enabling Studies, Launches Four Pharma Talks
VRXA•VERAXA Biotech announced its lead BiTAC candidate entered IND-enabling toxicology studies, with completion expected in Q4 2026 and preclinical proof-of-concept underway for two additional candidates targeting oncology and autoimmune indications. The company initiated strategic partnering discussions with four pharmaceutical firms, structuring potential licensing agreements with upfront payments, milestone fees and royalties.
1. BiTAC Pipeline Progress
VERAXA’s lead BiTAC candidate has entered IND-enabling toxicology studies, with data expected by Q4 2026. Two additional BiTAC assets are now in preclinical proof-of-concept testing, focusing on oncology and autoimmune indications to validate efficacy and safety profiles.
2. Partnering Strategy
The company has opened strategic discussions with four pharmaceutical firms to license its BiTAC technology. Proposed deal structures include upfront payments, milestone fees tied to development and regulatory milestones, and royalties on future product sales, aiming to secure collaborations by year-end.
